Kidney Disease News and Research

RSS

New data on Merck’s odanacatib for osteoporosis in postmenopausal women presented at 32nd ASBMR

New data on odanacatib, an investigational cathepsin-K (Cat-K) inhibitor in development for the treatment of osteoporosis in postmenopausal women, were presented at the 32nd Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in Toronto, Canada.

19 Oct 2010

14 global studies on osteoporosis medications FORTEO and EVISTA to be presented at ASBMR 2010

Eli Lilly and Company today announced that a total of 14 U.S. and global studies involving its osteoporosis medications, FORTEO® [teriparatide (rDNA origin) injection] and EVISTA® (raloxifene HCl tablets), will be presented at the American Society for Bone and Mineral Research (ASBMR) 2010 Annual Meeting from October 15-19 in Toronto, ON, Canada.

18 Oct 2010

African-American children have higher risk of hypertension

Persistently high blood pressure, or hypertension, may spell worse heart trouble for black children under the age of 13 than for other children of the same ages, according to research led by scientists at Johns Hopkins Children's Center and published in the November issue of Pediatrics.

18 Oct 2010

FDA plans to revoke knee implant approval following intense political pressure for its approval

The Food and Drug Administration on Thursday said it planned to revoke a medical-device company's right to sell a knee implant called Menaflex after an unprecedented yearlong review concluded the agency erred in allowing it on the market

18 Oct 2010

FibroGen announces initiation of FG-3019 phase 2 study for reversing liver fibrosis

FibroGen, Inc. today announced initiation of a phase 2 study to compare the efficacy of FG-3019, a human monoclonal antibody against connective tissue growth factor (CTGF), with placebo in reversing liver fibrosis (scarring of the liver) due to chronic infection with hepatitis B virus (HBV).

15 Oct 2010

Genzyme reports five-year patient data from Phase 2 multiple sclerosis trial

Genzyme Corporation today reported five-year patient data from its completed Phase 2 multiple sclerosis (MS) trial. This sub-group analysis found that nearly 90 percent of alemtuzumab-treated patients were free of sustained accumulation of disability, and that patients receiving alemtuzumab also maintained improved mean disability scores and a low risk of relapse over the 60-month follow-up period.

15 Oct 2010

Improving muscle mass benefits kidney disease patients

Kidney disease patients are healthier and live longer if they've beefed up their muscles, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). The results suggest that patients may benefit from pumping iron or taking medications to boost their lean body mass.

14 Oct 2010

ERYtech Pharma, Genzyme enter collaboration to develop novel therapeutic enzyme formulation

ERYtech Pharma is pleased to announce it has signed a collaborative research agreement with Genzyme Corporation to explore the feasibility of developing a novel therapeutic enzyme formulation using ERYtech's proprietary technology.

13 Oct 2010

Kuwait Healthy Life Study to examine metabolic health in children

In the face of a dramatic worldwide increase in adolescent obesity and Type 2 diabetes, The Forsyth Institute today announced a research alliance with the Dasman Diabetes Institute of Kuwait to initiate studies that could lay a scientific basis for prevention. This collaboration, called The Kuwait Healthy Life Study, will examine conditions in children that predispose them to obesity and Type 2 diabetes.

13 Oct 2010

Challenges in provision of high-quality health care at end of life

Health care in the last six months of life has become progressively more expensive for patients with heart failure both among Medicare beneficiaries in the United States and older adults in Canada, with a high rate of hospitalizations in the final six months of life in both countries, according to two reports posted online today that will be published in the February 14 print issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

12 Oct 2010

ESC pleased with European Health Award recognition for Chronic Disease Alliance

The European Society of Cardiology is delighted to see the European Health Award 2010 handed to the Chronic Disease Alliance at the 13th European Health Forum held in Gastein 6 - 9 October 2010.

11 Oct 2010

Abbott to withdraw Meridia medicine from the U.S. market

Abbott will voluntarily withdraw Meridia (sibutramine) from the U.S. market at the request of the U.S. Food and Drug Administration (FDA).

11 Oct 2010

Genzyme board of directors vote to reject tender offer from Sanofi-Aventis

Genzyme Corp. announced today that its board of directors has voted unanimously to reject the unsolicited $69.00 per share tender offer from Sanofi-Aventis, and the board recommends that Genzyme shareholders not tender their shares to Sanofi-Aventis pursuant to the offer.

8 Oct 2010

Lowering blood pressure may reduce risk of kidney disease progression

Keeping blood pressure at a low level in African-Americans with kidney disease may slow the progression of the condition in patients with proteinuria, UT Southwestern Medical Center researchers found in a national study published in The New England Journal of Medicine.

7 Oct 2010

New report focuses on management of renal anemia amongst dialysis, later stage CKD patients

BioTrends Research Group, Inc. recently published its TreatmentTrends: Renal Anemia in China report. This report is based on survey results from 150 nephrologists in clinical practice in China and qualitative interviews conducted with ten thought leaders in nephrology. The report examines the demographics of nephrology practice in China and focuses specifically on the management of renal anemia amongst dialysis and later stage chronic kidney disease patients.

7 Oct 2010

Raloxifene drug may be useful in treating kidney disease in women: Study

The osteoporosis drug raloxifene may be useful in treating kidney disease in women, suggests a new study led by Michal Melamed, M.D., M.H.S., assistant professor of medicine and epidemiology & population health at the Albert Einstein College of Medicine of Yeshiva University.

7 Oct 2010

Interim data from HyQ Phase III clinical study in primary immune deficiency presented at 26th ESID

Data from interim analyses of a Phase III clinical study in patients with primary immune deficiency (PID) who received Baxter's HyQ were presented at the 26th meeting of the European Society for Immunodeficiencies (ESID) in Istanbul, Turkey. HyQ is an immune globulin (IG) therapy facilitated subcutaneously by recombinant human hyaluronidase, a dispersion and permeation enhancer.

From Baxter International Inc. 6 Oct 2010

Podocytes key to development of kidney failure in diabetes

Diabetes is the leading reason for kidney failure in the world, resulting in patients requiring dialysis or kidney transplantation. New research has found a cell in the kidney called the podocyte could be the key to understanding why this happens.

6 Oct 2010

Amgen to present oncology portfolio results at ESMO Congress

Amgen today announced that results from several important studies from the Company's ncology portfolio will be presented at the 35th European Society for Medical Oncology (ESMO) Congress, Oct. 8-12, 2010, in Milan, Italy.

6 Oct 2010

Insulin-sensitizing drugs may offer new treatments for kidney failure

Evidence reported in the October issue of Cell Metabolism, a Cell Press publication, offers a completely new explanation for why people with diabetes account for more than half of all patients requiring dialysis or kidney transplantation. It appears that insulin has a significant influence on the structure and proper function of a particular group of very specialized cells, known as podocytes, that are integral to the kidney's ability to do its job filtering blood.

6 Oct 2010